Approx.280 pages - Discusses underlying cellular and molecular mechanisms altered in protein-associated neurodegenerative disorders - Describes methods for detection and analysis of protein aggregates - Features advancements in therapeutics and emerging techniques to treat these disorders - Covers implications in a variety of neurodegenerative diseases, including Alzheimer's, Parkinson's, ALS, Creutzfeldt-Jakob disease, Cystic fibrosis, Gaucher's disease, and Polyglutamine diseases, including Huntington's and other related proteinopathies
Autorentext
Dr. Gogia is a Post-Doctoral Associate at Yale. Having completed her PhD degree at the University of Dayton, and Cornell University's International Agriculture and Rural Development Program (IARD) she was awarded the Gerald L. Willis Award of Excellence for Outstanding Teaching in 2019. Her current work focuses on understanding cellular and molecular mechanisms underlying polyglutamine diseases, namely the identification and validation of genetic modifiers which can serve as potential therapeutic targets and can ameliorate the onset or progression of neurodegenerative diseases.